Harvard study questions citizens’ preparedness for anthrax attack

Published on February 22, 2010 by Nick Rees

A recent study by researchers at the Harvard School of Public Health found that 89 percent of Americans, in the event of a significant anthrax bioattack, would follow public health recommendations in obtaining antibiotics. Read More

Nanoviricides teams up with UC – Berkeley professor to test dengue virus drug candidates

Published on February 17, 2010 by Nick Rees

A research and development agreement has been signed between NanoViricides, Inc., and the laboratory of Dr. Eva Harris at the University of California – Berkeley to evaluate the effectiveness of Nanoviricides drug candidates against dengue viruses. Read More

Scott Habig joins Human Genome Sciences

Published on February 3, 2010 by Nick Rees

Scott Habig has joined Human Genome Sciences, Inc., as vice president of sales. Read More

Study published by Soligenix on characteristics of ricin A chain

Published on December 29, 2009 by Nick Rees

Soligenix, Inc., has announced the publication of an article that details the characteristics of several immunodominant regions of ricin A chain – the antigenic component of Rivax – in the January 2010 edition of Infection and Immunity. Read More

Positive results announced for Restanza in treatment of inhaled tularemia

Published on December 17, 2009 by Ted Purlain

Positive top-line results have been announced by Advanced Life Sciences Holdings, Inc., for its once-a-day, oral antibiotic Restanza to treat inhaled lethal doses of tularemia. Read More

Scientists Announce Possible Treatment for Deadly Virus

Published on November 12, 2009 by Pat Dulnier

Emergent BioSolutions appoints Ronald Richard to board of directors

Published on November 11, 2009 by Ted Purlain

Emergent BioSolutions establishes office in Germany

Published on November 10, 2009 by Paul Tinder

FDA to discuss experimental drug’s effectiveness against anthrax

Published on October 26, 2009 by Mary J. Lewis